Recently Featured

Big obesity bets and China’s rise fuel potential $2T in 2032 drug sales: Evaluate

June 29, 2026
Recent analyses indicate that the global pharmaceutical market could see drug sales soar to $2 trillion by 2032, driven primarily by significant investments in obesity treatments and the expanding influence of the Chinese market. This projection highlights a pivotal shift in therapeutic focus, as stakeholders increasingly prioritize obesity management solutions amidst rising global obesity rates.…

Sanofi Swaps R&D Leaders; Merck’s Prometheus Deal Pays Dividends

June 29, 2026
Houman Ashrafian is leaving his position at Sanofi to pursue a new opportunity, marking a significant leadership change within the company’s R&D division. This transition comes at a crucial time as Sanofi seeks to enhance its innovation pipeline and address the evolving demands of the pharmaceutical landscape. Leadership changes in R&D can often signal shifts…

Confirmed Ebola Cases in Congo Outbreak Exceed 1,000 with 254 Deaths

June 29, 2026
BUNIA, Congo — Confirmed cases in the Ebola outbreak in eastern Congo have reached 1,003, including 254 deaths, officials reported, highlighting the severe public health crisis as tracing contacts of infected individuals remains a significant challenge. The outbreak, which has been concentrated in Ituri province since its declaration on May 15, underscores the complexities of…

AbbVie deepens immunology legacy in $10.9bn Apogee buyout

June 29, 2026
AbbVie has announced its acquisition of Apogee Therapeutics for $10.9 billion, a strategic move aimed at enhancing its portfolio in the competitive immunology sector. This acquisition comes at a time when the demand for innovative therapies in immunology is surging, driven by an increasing prevalence of autoimmune diseases and a growing emphasis on personalized medicine.…

Ongoing Cases